Thousand Oaks, CA, June 28, 2021 (GLOBE NEWSWIRE) — CBDual Biotechnology Corp’s guardian firm, THC Farmaceuticals, Inc (OTC: CBDG), developer of a novel line of premium CBD based mostly oral well being merchandise in addition to Dr. Rubin’s Nervousness Tablets right this moment introduced the ultimate departure of CBDG’s Chairman and CEO.
Senator Mike Gravel, former CEO of THC Farmaceuticals, Inc (OTC: CBDG), who in his personal phrases “introduced judgment to the desk based mostly upon expertise and accomplishment,” sadly departed from his household residence in California this weekend. “Senator Gravel’s wealth of expertise with public insurance policies, politics and personal enterprise made him one of the best candidate for CEO, and helped CBDG and the whole hashish sector’s efforts to beat federal criminalization insurance policies,” stated Firm Administration. “His stature as a famous politician demanded a response for his added bravery of heading up not one however two Hashish-related publicly traded corporations, the primary being Hashish Sativa, Inc.”
Though greatest recognized for filibustering the Pentagon Papers into the Congressional Document and contributing to the top to the army draft and Vietnam Warfare, Senator Gravel was an outspoken opponent of Nixon’s battle on medicine. “Mike continued breaking obstacles when becoming a member of CBDS’ crew and later ours,” Firm Administration went on to say. “The stigma of being a hashish firm had not been overcome at that very early time when he first joined CBDS’s board and later that of CBDG, and it took nice braveness. Mike was a resolute advocate of non-public freedom and hashish legalization. This is trying as much as our beloved Mike Gravel and his eternal reminiscence.”
About CBDual Biotechnology Corp.
THC Farmaceuticals, Inc.: (OTC: CBDG), via its subsidiary, CBDual Biotechnology Corp., is a pharmaceutical start-up firm that focuses on growing merchandise based mostly on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The Firm’s facility is situated in Southern California. We offer easy accessibility for sufferers to take part in medical trials of recent medical hashish drugs, therapies, and merchandise. CBDual Biotechnology Corp is a privately held, U.S. Based mostly Biotechnology firm with proprietary expertise for enhanced oral supply of bioactive cannabinoids. This expertise promotes general oral well being as a result of greater effectiveness of the supply methodology. The Firm was based in 2016 and is headquartered in California, with its R&D within the U.S. and Israel. On November 26, 2018, the Firm took steps to turn out to be the world’s first public Firm to enter the magic mushroom area, subsequently forming its subsidiary, Medical Mushrooms Ltd. Lately the Firm has begun analysis on psilocybin for the aim of conducting medical trials involving the mixture of genetic testing and micro-dosing of psilocybin formulations. We’re well-positioned to start medical trials involving psilocybin since we now have already cleared a path for cannabis-related medical trials. The aim of this division is to have interaction in superior analysis of the rising area of interest of pharmaceutical-grade medicinal mushrooms, together with psychedelics. The Firm has registered the next domains:
About Hashish Sativa, Inc.:
Hashish Sativa, Inc. (“CBDS”) is engaged within the licensing of cannabis-related mental property, advertising and branding for cannabis-based services and products, operation of cannabis-related expertise providers, and ancillary enterprise actions. CBDS licenses the “hello” and “White Rabbit” manufacturers, holds a U.S. patent on the Ecuadorian Sativa pressure of Hashish, a U.S. Patent for a marijuana lozenge, and operates its major subsidiary PrestoDoctor® (https://prestodoctor.com).
This press launch accommodates “forward-looking statements.” Though the forward-looking statements on this launch mirror the nice religion judgment of administration, forward-looking statements are inherently topic to recognized and unknown dangers and uncertainties that will trigger precise outcomes to be materially totally different from these mentioned in these forward-looking statements. Readers are urged to fastidiously overview and think about the assorted disclosures made by us in our reviews filed with the Securities and Alternate Fee, together with the chance elements that try and advise events of the dangers that will have an effect on our enterprise, monetary situation, outcomes of operation and money flows. If a number of of those dangers or uncertainties materialize, or if the underlying assumptions show incorrect, our precise outcomes might range materially from these anticipated or projected. Readers are urged to not place undue reliance on these forward-looking statements, which communicate solely as of the date of this launch. We assume no obligation to replace any forward-looking statements as a way to mirror any occasion or circumstance that will come up after the date of this launch.
SOURCE: CBDual Biotechnology Corp.
Copyright 2021 GlobeNewswire, Inc.